KaydedilenlerDerginizi ekleyin

Dergiler / Anatolian Current Medical Journal / 2022 / Cilt: 4 - Sayı: 1

Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus

Hacer KAYHAN KAYA
Abdurrahman ŞERMET
Zafer PEKKOLAY
Ezel TAŞDEMİR
Dilek AYGÜN KEŞİM
Sayfa
113–119
Yayın Tarihi
2022-01-24
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: The visfatin levels of the OD and ND were significantly higher compared to those of their control groups (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of this study was to determine the serum visfatin, eotaxin and fetuin-A levels in patients with normal BMI and overweight type 2 diabetes mellitus (T2DM).
📊
Temel Bulgular & Veri:Material and Method: This study perform in 30 T2DM patients and in 20 healthy subjects.
💡
Sonuç & Katkı:Results: The visfatin levels of the OD and ND were significantly higher compared to those of their control groups (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Visfatin · eotaxin · fetuin-A

Abstract

Objective: The aim of this study was to determine the serum visfatin, eotaxin and fetuin-A levels in patients with normal BMI and overweight type 2 diabetes mellitus (T2DM). Material and Method: This study perform in 30 T2DM patients and in 20 healthy subjects. Test subjects were divided into four groups as two diabetics and two controls. Diabetics with a body mass index (BMI) of 26.2-29.9 kg/m2 were included in the overweight diabetic group (OD), and those with a body mass index of 20.9-24.9 kg/m2 were included in the normal BMI diabetic group (ND). The volunteers in the control group were also divided into two groups as overweight (OC) and normal BMI (NC). Smoking and alcohol users were not included in the study. In addition, patients with significant diabetic complications such as retinopathy, hypertension, neuropathy, renal failure, and cardiovascular disease were excluded from the study. The serum visfatin eotaxin and fetuin-A levels were measured using the ELISA method. The Mann-Whitney U test was used to compare the data of the groups, while Spearman’s analysis was applied for the correlations. Results: The visfatin levels of the OD and ND were significantly higher compared to those of their control groups (p

🔖

Bu Makaleye Atıf Yap

KAYA, H. K., ŞERMET, A., PEKKOLAY, Z., TAŞDEMİR, E., KEŞİM, D. A. (2022). Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus. Anatolian Current Medical Journal, Cilt: 4 - Sayı: 1, 113–119. https://ajindex.com/articles/733798

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 2015; 38: S1–S2. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-9. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
  2. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol 2011; 8; 8: 228-36. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-57. Opara E. Nutrition and diabetes. Pathophysiology and management. Taylor and Francis Group 2006. Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. Morb Mortal Wkly Rep. (MMWR) 2004; 19; 53: 1066-8.
  3. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest 2003; 112: 1821-30.
  4. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005 Jan 21; 307: 426-30.
  5. Jean-Baptiste S, O’Toole EA, Chen M, Guitart J, Paller A, Chan LS. Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. Clin Exp Immunol 2002; 127: 470-8.
  6. Vasudevan AR, Wu H, Xydakis AM, et al. Eotaxin and obesity. J Clin Endocrinol Metab 2006; 91: 256-61.
  7. Mori K, Emoto M, Yokoyama H, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 2006; 29: 468. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006; 113: 1760-7.
  8. Ix JH, Wassel CL, Kanaya AM, et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008; 300: 182-8.
  9. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 2006; 350: 437-43.
  10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fast